LearnGlossaryMarketStocksSuperinvestorsSign in

ETON

Eton Pharmaceuticals, Inc.

Healthcare · $1.6B market cap

Verdict

We can't put a fair value on ETON right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth8.5% a year✗
Sales growth36.9% a year✓
Free cash flow growth49.1% a year✓
Return on invested capital-3.4%✗

Follow ETON

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ETON. In Q2 2026, 1 added. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$1.6M

45,379 shares

Moves in Q2 2026

Added: Polen Capital Management

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate…

Drug Manufacturers - Specialty & Generic

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works